Mammaglobin A (Mam-A) was reported to be highly specific to the mammary gland and upregulated in most mammary carcinomas of different genotypes, including TNBCs10-12 and it has been proposed as a promising molecular target for breast cancer therapy.12,13 However, despite a few scattered studies, a robust targeting system based on Mam-A is still unavailable due to the lack of understanding of its immune-epitopes and the lack of a proper ligand with high affinity. This evidence concerns the gene SCGB2A2 and breast carcinoma.